Dr. Harriet L. Robinson, Chief Scientific Officer at GeoVax Inc., a biotech company specializing in the development of HIV/AIDS vaccines, has multi-protein clade B DNA/MVA and MVA/MVA vaccine regimens in clinical trials through the US HIV vaccine Trials Network (HVTN). The vaccine was developed in Dr. Robinson's former laboratory at the Emory Vaccine Center in collaboration with Dr. Bernard Moss's laboratory at the US NIH and researchers at the US Centers for Disease Control and Prevention. The vaccine DNA is used to prime the immune response and the recombinant MVA to boost the immune response. The recombinant MVA can also be used to prime and boost the immune response. Dr. Robinson co-founded GeoVax to facilitate taking the vaccine from the research laboratory to clinical use. Dr. Robinson, former Asa Griggs Candler Professor of Microbiology and Immunology at Emory University and Chief of the Division of Microbiology and Immunology at the Yerkes National Primate Research Center, is internationally recognized for her work on HIV/AIDS vaccines, her pioneering studies on the use of recombinant DNA for vaccination and her seminal studies on insertional mutagenesis and oncogene transduction in retroviral induced cancers. She received her Ph.D. from the Massachusetts Institute of Technology and her post doctoral training at the Virus Laboratory, University of California Berkeley. Dr. Robinson is active on several Editorial Boards and has consulted for the US NIH, the US Food and Drug Administration, the World Health Organization, and the Gates Foundation.
Blogged on behalf of Milana Shapira and Sophia Doll
Dr. Harriet Robinson spoke about the GeoVax DNA/MVA and MVA/MVA HIV vaccines. Both vaccines express virus like particles (VLP) and have regimens in clinical trials through the US HIV vaccine Trials Network (HVTN). These cost effective vaccines have already been tested in 450 people and have passed clinical phase II trial. Phase I and II produced positive results for safety, immunogenicity and consistency. The protective success is principally due to co-expression of GM-CSF (immune modulating factor) to enhance mucosal and systemic antibody responses. Also experiments in SIV models with DNA/MVA GeoVax vaccines showed good CD4 and CD8 T cell and antibody binding responses.
The presentations from the event will be made available from the 1st November.